Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in adolescent moderate-to-severe atopic dermatitis
NCT06277765Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Mar 2024; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06277765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277765.